Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Atea Pharmaceuticals, Inc. - common stock (AVIR)
US:NASDAQ Investor Relations:
investors.aviragentherapeutics.com/news-releases/news-release-details/aviragen-therapeutics-and-vaxart-enter-merger-agreement
Company Research
Source: Yahoo! Finance
Atea Pharmaceuticals, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter ( see the details here Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Fourth Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up for your questions. I would now like to turn the call over to Jonae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Ms. Barnes, please proceed. Jonae Barnes: Good afternoon, everyone, and welcome to Atea Pharmaceuticals fourth quarter and full year 2023 financial results and business update conference call. Earlier today, we issued a press release, which outlines the topics we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website a
Show less
Read more
Impact Snapshot
Event Time:
AVIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVIR alerts
High impacting Atea Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
AVIR
News
- Global Dengue Pipeline Landscape Report 2024: Therapeutic Assessment and Drug Analysis of 20+ Drugs [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsGlobeNewswire
- Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
AVIR
Earnings
- 2/28/24 - Miss
AVIR
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- 2/28/24 - Form 10-K
- AVIR's page on the SEC website